Article
Development of a Novel Anti-CD44 Variant 5 Monoclonal Antibody C<sub>44</sub>Mab-3 for Multiple Applications against Pancreatic Carcinomas
2023-01-31
Abstract excerpt
Pancreatic cancer exhibits a poor prognosis due to the lack of early diagnostic biomarkers and the resistance to conventional chemotherapy. CD44 has been known as a cancer stem cell marker, and plays tumor promotion and drug resistance in various cancers. Especially, the splicing variants are overexpressed in many carcinomas, and play essential roles in the cancer stemness, invasiveness or metastasis, and resistan...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 72453ab6-4104-5a96-aea3-80fca3c009ad
- DOI
- 10.20944/preprints202301.0581.v1
